Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITED: Ustekinumab Long-term Extension Study in Pediatric Participants
NCT05092269Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ustekinumab in Crohn's disease, ulcerative colitis (UC), psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Oct 2021; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05092269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092269.